Tuesday, 02 January 2024 12:17 GMT

Structure Therapeutics To Participate In The Jefferies Global Healthcare Conference


Date:

(MENAFN- GlobeNewsWire - Nasdaq) SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced that management will participate in the Jefferies Global Healthcare Conference being held November 16-19, 2026 in London, UK.

Jefferies Global Healthcare Conference
Date: Tuesday, November 17
Format: Fireside chat and 1x1 meetings
Time: 12:00 PM GMT
Location: London, UK

The live and archived webcasts will be accessible from the company's website at and replays will be available for at least 90 days.

About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit .

Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
...

Jennifer Robinson
Structure Therapeutics Inc.
...

Media:
Dan Budwick
1AB
Dan@1abmedia.com


MENAFN04112026004107003653ID1111914350


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search